A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)

Inclusion Criteria: * Subject must meet ALL of the following inclusion criteria to be enrolled in the study: 1. Male or Female age 20 years or older; 2. Proximal aortic neck is 17-31mm in diameter; 3. Supra-renal aorta, at 20mm above the anticipated landing location, is smaller than the nominal diameter of the aortic bifurcate prosthesis to be used; 4. Infra-renal aortic neck is ≥10mm in length with supra-renal and infra-renal angulations ≤60°; 5. Subject has at least one of the following: 1. AAA size \> 5.0 cm; 2. Increase of the AAA diameter of \> 0.5 cm over the last 6 months; 6. Abdominal treatment length (lowest renal artery origin to the aortic bifurcation) ≥ 9.4cm; 7. Aortic bifurcation \>18mm in diameter; 8. Iliac landing zone ≥15mm in length; 9. Iliac landing zone 7-22mm in diameter; 10. Minimum access vessel size of ≥ 5mm; 11. Minimum overall AAA treatment length (from lowest renal artery to distal landing zone) of 128 mm; 12. Women of child bearing potential must be non-pregnant, non-lactating, and not planning to become pregnant during the course of the trial; and have a negative urine or serum pregnancy test within 7 days prior to index procedure; 13. Provide written informed consent and as applicable written HIPAA authorization (For US sites only) prior to initiation of study procedures; 14. Willing to comply with the specified follow-up evaluation schedule. Exclusion Criteria: * Subjects will be excluded if ANY of the following exclusion criteria apply: 1. Vascular anatomy in which the placement of the stent-graft will cause occlusion of both internal iliac arteries or necessitates surgical occlusion of both internal iliac arteries; 2. Subject has one of the following: 1. Aneurysm sac rupture or leaking abdominal aortic aneurysm; 2. Mycotic, dissecting, or inflammatory abdominal aortic aneurysm; 3. Clinically significant acute vascular injury due to trauma; 3. Significant aortic or iliac mural thrombus, plaque or calcification that would compromise fixation and seal of the device; 4. A conical aortic neck defined as \>3mm distal increase over a 10mm length in the planned seal zone; 5. Thoracic aortic aneurysm ≥45mm; 6. Any aortic dissection; 7. Morbid obesity (BMI \>40.0 kg.m2) or other clinical conditions that limit required imaging studies or visualization of the aorta; 8. Renal insufficiency (Creatinine \> 2.0mg/dL) or subject on renal dialysis; 9. Known allergy or intolerance to nickel titanium (nitinol) , Polyethylene terephthalate (PET), or polytetrafluoroethylene (PTFE); 10. Known contraindication to undergoing angiography or anticoagulation (e.g. contrast allergies which cannot be treated); 11. Connective tissue disorder (such as Marfan's Syndrome or Ehlers-Danlos Syndrome); 12. Coagulopathy, bleeding disorder, or other hypercoagulable state; 13. Organ transplant recipient or subject requiring systemic immunosuppressant therapy; 14. Cerebral vascular accident (CVA), MI, or intracranial bleeding within 3 months prior to the procedure; 15. Active infection or chronic systemic illness at the time of index procedure that may interfere with the study objectives; 16. Major surgical procedure within 1 month prior to the index procedure or pre-planned within 1 month afterwards; 17. Co-existing condition with a life expectancy of less than 2 years at time of procedure; 18. Current or planned participation in any other investigational drug or medical device clinical study that has not completed primary endpoint(s) evaluation; 19. Existing AAA surgical graft and/or a AAA stent-graft system; 20. Other medical, social, or psychological issues that in the opinion of the investigator preclude the subjects from receiving this treatment, and the procedures and evaluations pre- and posttreatment.